Trevi Therapeutics Q3 net loss widens 82% to $21.45 million
TRVI•Trevi Therapeutics’ third-quarter 2026 net loss widened 82% year over year to $21.45 million. The company reported $299.4 million in quarter-end cash, cash equivalents and marketable securities, with runway expected into 2030.
1. Quarterly results
Trevi Therapeutics’ third-quarter net loss widened 82% year over year to $21.45 million. Research and development expenses rose 89% to $19.06 million, primarily due to increased clinical development spending.
2. Clinical trial updates
Both Phase 3 OCEAN trials are recruiting patients with IPF-related chronic cough, and OCEAN-2 topline results are expected in the second half of 2027. A Phase 2 trial for non-IPF ILD-related chronic cough is expected to start in the first quarter of 2027, subject to FDA protocol review.
